Submitted by: Submitted by randhir
Views: 448
Words: 1832
Pages: 8
Category: Business and Industry
Date Submitted: 01/22/2011 10:41 PM
Riddhi Siddhi Gluco Biols Ltd
Company Overview
Riddhi Siddhi Gluco Biols Ltd. is the largest Indian starch and starch derivatives company. It possesses a basket of 35 products. Its product profile comprising maize starch powder, liquid glucose, dextrose monohydrate, melt dextrin, high maltose corn syrup, dextrose syrup and allied by-products. It has three manufacturing facilities in Gokak (Karnataka), Pantnagar (Uttranchal), Viramgam (Gujarat) and seven marketing offices in North, South and West India. It has export presence across 25 countries.
Business model
Riddhi Siddhi Gluco Biols Ltd. is having a unique business strategy. They have established there production plants at strategic location from where they can source raw material within the radius of 350 Kms. The company is able to source raw material at lower cost by saving transportation cost. The company has its establishment in such states where it enjoys tax and excise benefits at locations like Gokak and Rudrapur. Company is enjoying sales tax deferment at Gokak plant till 2014. States like Karnataka and Andhra are producing the highest maize. Gokak Plant is situated in Karnataka near one of the largest corn gainers of India. For other plants like Rudrapur, company is able to source raw material from the state like UP and Bihar.
RSGBL entered into a strategic alliance with the French company Roquette Freres which is world’s largest corn processing company. This will facilitate the company in the transfer of technology know how and help company to enhance its standards and technology leadership in the industry.
Raw material producer for leaders of growing sectors
[pic]
RSGBL (Riddhi Siddhi Gluco Biols Ltd) is having strong client base of the different business segments offering portfolio of more than 30 products. The company is providing starch products to the industries like Food, Pharma, Textile, Paper, Confectionaries, Pharma sector is likely to grow by 14 to 15% CAGR for 10 years....